Objectives To replicate previous analyses on the effectiveness of the English human papillomavirus (HPV) vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) using 12 additional months of follow-up, and to investigate effectiveness across levels of socioeconomic deprivation.
Design Observational study.
Setting England, UK.
Participants Women aged 20-64 years resident in England between January 2006 and June 2020 including 29 968 with a diagnosis of cervical cancer and 335 228 with a diagnosis of CIN3. In England, HPV vaccination was introduced nationally in 2008 and was offered routinely to girls aged 12-13 years, with catch-up campaigns during 2008-10 targeting older teenagers aged <19 years.
Main outcome measures Incidence of invasive cervical cancer and CIN3.
Results In England, 29 968 women aged 20-64 years received a diagnosis of cervical cancer and 335 228 a diagnosis of CIN3 between 1 January 2006 and 30 June 2
This seminar focuses on the case study of human papillomavirus (HPV) vaccination in the UK. The HPV vaccine is now offered to girls and boys aged 12–13, as well as to men who have sex with men. The vaccine helps prevent cervical, head and neck, and anogenital cancers caused by HPV infection, as well as genital warts.
HPV vaccine reduced cervical cancer rates by 87% in women, UK study finds cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.